ReviewCancer reports (Hoboken, N.J.)2025
Multiple Skin Cancers Associated With Hydroxyurea: Case Report and Review of Literature.
Review in Cancer reports (Hoboken, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Multiple Skin Cancers Associated With Hydroxyurea: Case Report and Review of Literature.Cancer reports (Hoboken, N.J.) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHydroxyurea (HU) is an antimetabolite used to treat different myeloproliferative disorders, including chronic myeloid leukemia, polycythemia vera, and essential thrombocytopenia (ET). HU has a significant effect on the treatment of myeloproliferative disease. RECENT
findingsA 54-year-old woman with a history of ET from 15 years ago presented with multiple erythematous plaques and ulcers on the face and extremities from 2 years ago. She had multiple SCCs, Bowen, and AK on both extremities and face. We reviewed and summarized the literature on the relationship between HU and nonmelanoma skin cancer (NMSC) between 1991 and 2022. Sixty cases (37 men and 23 women) were evaluated. The participants' mean age was 66.73 ± 9.80 years. They received the HU therapy for 9.17 ± 4.29 years. The latency period to the occurrence of symptoms in patients with HU-related skin cancer was 7.33 ± 4.40 years. The HU dose in these patients ranged from 1.21 ± 0.53 g/d. Among NMSCs, SCCs are more frequently associated with the HU treatment, followed by AKs, BCCs, and Bowen.
conclusionHealthcare providers should be aware of skin cancer risks; patients receiving long-term HU therapy should be screened for early diagnosis and provided with preventive measures and appropriate treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.